Immunogenic and tolerogenic cell death
- PMID: 19365408
- PMCID: PMC2818721
- DOI: 10.1038/nri2545
Immunogenic and tolerogenic cell death
Abstract
The immune system is routinely exposed to dead cells during normal cell turnover, injury and infection. Mechanisms must exist to discriminate between different forms of cell death to correctly eliminate pathogens and promote healing while avoiding responses to self, which can result in autoimmunity. However, an effective immune response against host tissue is often needed to eliminate tumours following treatment with chemotherapeutic agents that trigger tumour cell death. Consequently, a central problem in immunology is to understand how the immune system determines whether cell death is immunogenic, tolerogenic or 'silent'.
Figures
Similar articles
-
Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells.Immunity. 2011 Oct 28;35(4):456-66. doi: 10.1016/j.immuni.2011.08.011. Immunity. 2011. PMID: 22035838 Free PMC article. Review.
-
Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy.Biochem Pharmacol. 2018 Jul;153:12-23. doi: 10.1016/j.bcp.2018.02.006. Epub 2018 Feb 10. Biochem Pharmacol. 2018. PMID: 29438676 Review.
-
Inducers of immunogenic cancer cell death.Cytokine Growth Factor Rev. 2013 Aug;24(4):319-33. doi: 10.1016/j.cytogfr.2013.01.005. Epub 2013 Feb 5. Cytokine Growth Factor Rev. 2013. PMID: 23391812 Review.
-
The inducers of immunogenic cell death for tumor immunotherapy.Tumori. 2018 Jan-Feb;104(1):1-8. doi: 10.5301/tj.5000675. Tumori. 2018. PMID: 28967094 Review.
-
Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer.Immunity. 2012 Mar 23;36(3):322-35. doi: 10.1016/j.immuni.2012.03.004. Immunity. 2012. PMID: 22444630 Review.
Cited by
-
Ironing out the role of ferroptosis in immunity.Immunity. 2024 May 14;57(5):941-956. doi: 10.1016/j.immuni.2024.03.019. Immunity. 2024. PMID: 38749397 Review.
-
Precise modulation and use of reactive oxygen species for immunotherapy.Sci Adv. 2024 May 17;10(20):eadl0479. doi: 10.1126/sciadv.adl0479. Epub 2024 May 15. Sci Adv. 2024. PMID: 38748805 Free PMC article. Review.
-
Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells.J Immunother Cancer. 2024 Apr 11;12(4):e007588. doi: 10.1136/jitc-2023-007588. J Immunother Cancer. 2024. PMID: 38609101 Free PMC article.
-
Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology.Eur J Med Res. 2024 Apr 9;29(1):224. doi: 10.1186/s40001-024-01822-7. Eur J Med Res. 2024. PMID: 38594732 Free PMC article. Review.
-
Personalized treatment concepts in extraocular cancer.Adv Ophthalmol Pract Res. 2024 Mar 1;4(2):69-77. doi: 10.1016/j.aopr.2024.02.003. eCollection 2024 May-Jun. Adv Ophthalmol Pract Res. 2024. PMID: 38590555 Free PMC article. Review.
References
-
- Medzhitov R, Janeway CA., Jr. Decoding the patterns of self and nonself by the innate immune system. Science. 2002;296:298–300. - PubMed
-
- Zitvogel L, et al. Immune response against dying tumor cells. Adv Immunol. 2004;84:131–179. - PubMed
-
- Gaipl US, et al. Clearance deficiency and systemic lupus erythematosus (SLE) J Autoimmun. 2007;28:114–121. - PubMed
-
- Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301–305. - PubMed
-
- Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–1462. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- F32 EY006765/EY/NEI NIH HHS/United States
- R01 AI047891/AI/NIAID NIH HHS/United States
- R01 EY006765/EY/NEI NIH HHS/United States
- EY06765/EY/NEI NIH HHS/United States
- EY15570/EY/NEI NIH HHS/United States
- P01 CA069381-140010/CA/NCI NIH HHS/United States
- R01 AI044828/AI/NIAID NIH HHS/United States
- R01 AI040646-14/AI/NIAID NIH HHS/United States
- R01 AI047891-11/AI/NIAID NIH HHS/United States
- P30 EY002687/EY/NEI NIH HHS/United States
- R01 EY015570/EY/NEI NIH HHS/United States
- R37 GM052735-19/GM/NIGMS NIH HHS/United States
- R37 GM052735/GM/NIGMS NIH HHS/United States
- EY02687/EY/NEI NIH HHS/United States
- R01 AI044828-12/AI/NIAID NIH HHS/United States
- P01 CA069381/CA/NCI NIH HHS/United States
- R01 AI040646/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources